Every material Form 8-K AIM ImmunoTech Inc. has filed with the SEC since September 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
AIM ImmunoTech furnished a new investor presentation, "The Ampligen Opportunity," and a November 5, 2026 press release describing the rationale for combining Ampligen with Revolution Medicines' daraxonrasib in pancreatic cancer. The filing reports no financial results and no new clinical data, and the company states the proposed combination remains investigational.
The Phase 2 DURIPANC topline results are expected in Q1 2027, with additional analyses anticipated in Q3 2027.
The DURIPANC Phase 1/2 study enrolled 28 patients and tests Ampligen with durvalumab (Imfinzi) in metastatic pancreatic cancer.
Ampligen is not approved by the U.S. Food and Drug Administration for pancreatic cancer, and the company says the combination's safety and efficacy have not been established.
AIM ImmunoTech Inc. exchanged approximately $400,000 of a November 18, 2025 promissory note held by Streeterville Capital, LLC into 1,749,434 shares of common stock at an average conversion price of about $0.228 per share. The transactions were carried out through two exchange agreements signed September 8 to September 9, 2026, and the shares were issued under a Securities Act exemption for exchanges with an existing holder. Because the new shares add to the outstanding share count, existing shareholders' ownership percentages are diluted, although the filing does not state the total share count.
Debt converted: approximately $400,000 of the Promissory Note dated November 18, 2025
Shares issued: 1,749,434 shares of common stock at an average conversion price of about $0.228 per share
Agreements dated September 8 to September 9, 2026, with Streeterville Capital, LLC; stockholders approved the conversion at a July 15, 2026 special meeting
Shares issued under Section 3(a)(9) of the Securities Act, with no commission paid for the exchange
AIM ImmunoTech Inc. exchanged about $450,000 of a November 18, 2025 promissory note held by Streeterville Capital, LLC for 1,921,441 shares of common stock, at an average conversion price of about $0.234 per share, under agreements dated September 3 and September 4, 2026. Stockholders had approved the conversion at a July 15, 2026 special meeting, and the shares were issued without SEC registration under a Section 3(a)(9) exemption.
Converted about $450,000 of the November 18, 2025 promissory note into 1,921,441 shares
Average conversion price of about $0.234 per share
Agreements signed September 3 and September 4, 2026 with Streeterville Capital, LLC
Stockholders approved the conversion at a special meeting held July 15, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every AIM ImmunoTech Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →